2025-2026 RSV Program Resources

General Resources

Product Monographs

Adverse Effects Following Immunization (AEFI)

Unlike vaccines, mAb are not reportable under the Health Protection and Promotion Act. Adverse Events Following Immunization (AEFI) experienced with Beyfortus should be managed as per your organizational policies and reported to Health Canada using their Side Effect Reporting Form. 

Letters from CMOH

CMOH Letter to HCPs - RSV - ENG - 2025-09-15
CMOH Letter to HCPs - RSV - FRE - 2025-09-15

Fact Sheets

Older Adult High Risk RSV Vaccine Program Fact Sheet - ENG - 2025-09-15
Older Adult High Risk RSV Vaccine Program Fact Sheet - FRE - 2025-09-15
Infant and High-Risk Children RSV Prevention Program Fact Sheet - ENG - 2025-09-15
Infant and High-Risk Children RSV Prevention Program Fact Sheet - FRE - 2025-09-15
Related Content
Adult Vaccines
Health Care Providers


List of links present in page
  1. https://www.wechu.org/vaccine-providers/rsv-program-resources
  2. https://www.ontario.ca/page/respiratory-syncytial-virus-rsv-prevention-programs#:%7E:text=Through%20the%20RSV%20Prophylaxis%20for,at%20high%20risk%20for%20RSV
  3. https://www.ontario.ca/page/respiratory-syncytial-virus
  4. https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/respiratory-syncytial-virus.htm
  5. https://ca.gsk.com/en-ca/products/arexvy/
  6. https://www.pfizer.ca/en/our-products/abrysvo-respiratory-syncytial-virus-stabilized-prefusion-f-dubunit-vaccine
  7. https://www.sanofi.com/assets/countries/canada/docs/products/vaccines/beyfortus-en.pdf
  8. https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting/consumer-side-effect-reporting-form.html
  9. https://www.wechu.org/sites/default/files/HSch%3B%20IMMS%20-%20Correspondence%20-%20CMOH%20Letter%20to%20HCP%20re%20RSV%20-%20ENG%20%288%7B2%7D29%7B2%7D2025%29%20%28ID%20315562%29.pdf
  10. https://www.wechu.org/sites/default/files/HSch%3B%20IMMS%20-%20Correspondence%20-%20CMOH%20Letter%20to%20HCP%20re%20RSV%20-%20FRE%20%288%7B2%7D29%7B2%7D2025%29%20%28ID%20315565%29.pdf
  11. https://www.wechu.org/sites/default/files/HSch%3B%20IMMS%20-%20Correspondence%20-%20Older%20Adult%20High%20Risk%20RSV%20Vaccine%20Program%20Fact%20sheet%20for%20HCP-%20ENG%20Aug%20%28ID%20315550%29.pdf
  12. https://www.wechu.org/sites/default/files/HSch%3B%20IMMS%20-%20Correspondence%20-%20Older%20Adult%20High%20Risk%20RSV%20Vaccine%20Program%20Fact%20sheet%20for%20HCP-%20FRE%20Aug%20%28ID%20315554%29.pdf
  13. https://www.wechu.org/sites/default/files/IMMS%20-%20Correspondence%20-%20Infant%20and%20High-risk%20Children%20RSV%20Prevention%20Program%20Factsheet%20for%20HCP%20%20-%20EN%20%28ID%20314986%29.pdf
  14. https://www.wechu.org/sites/default/files/IMMS%20-%20Correspondence%20-%20Infant%20and%20High-risk%20Children%20RSV%20Prevention%20Program%20Factsheet%20for%20HCP%20%20-%20FR%20%28ID%20314987%29.pdf
  15. https://www.wechu.org/tags/adult-vaccines
  16. https://www.wechu.org/tags/health-care-providers